The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 6 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: Cognitive dysfunction is often present in major depressive disorder (MDD). Several clinical trials have noted a pro-cognitive effect of antidepressants in MDD. The objective of the current systematic review and meta-analysis was to assess the pooled efficacy of antidepressants on various domains of cognition in MDD. METHODS: Trials published prior to April 15, 2015, were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Data from randomized clinical trials assessing the cognitive effects of antidepressants were pooled to determine standard mean differences (SMD) using a random-effects model. RESULTS: Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified. Antidepressants had a positive effect on psychomotor speed (SMD 0.16; 95% confidence interval [CI] 0.05-0.27; I(2) = 46%) and delayed recall (SMD 0.24; 95% CI 0.15-0.34; I(2) = 0%). The effect on cognitive control and executive function did not reach statistical significance. Of note, after removal of vortioxetine from the analysis, statistical significance was lost for psychomotor speed. Eight head-to-head randomized trials comparing the effects of selective serotonin reuptake inhibitors (SSRIs; n = 371), selective serotonin and norepinephrine reuptake inhibitors (SNRIs; n = 25), tricyclic antidepressants (TCAs; n = 138), and norepinephrine and dopamine reuptake inhibitors (NDRIs; n = 46) were identified. No statistically significant difference in cognitive effects was found when pooling results from head-to-head trials of SSRIs, SNRIs, TCAs, and NDRIs. Significant limitations were the heterogeneity of results, limited number of studies, and small sample sizes. CONCLUSIONS: Available evidence suggests that antidepressants have a significant positive effect on psychomotor speed and delayed recall.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found that antidepressants have small, statistically significant positive effects on psychomotor speed and delayed recall in major depressive disorder, but not on cognitive control or executive function. Head-to-head trials showed no statistically significant differences between antidepressant classes, and the psychomotor speed effect lost significance after removing vortioxetine.
Key findings
- In nine placebo-controlled randomized trials (2,550 participants), antidepressants improved psychomotor speed (SMD 0.16; 95% CI 0.05–0.27; I² = 46%) and delayed recall (SMD 0.24; 95% CI 0.15–0.34; I² = 0%). Effects on cognitive control (SMD 0.10; 95% CI −0.06 to 0.26; p = 0.21) and executive function (SMD 0.12; 95% CI −0.03 to 0.28; p = 0.12) were not statistically significant.
- Vortioxetine had the largest pooled effect size (0.34; 95% CI 0.17–0.50; p = 0.0001), followed by duloxetine (0.10; 95% CI −0.01 to 0.22). After removing vortioxetine, the psychomotor speed effect was no longer significant (SMD 0.08; 95% CI −0.02 to 0.18; p = 0.13).
- In head-to-head trials, no statistically significant difference was found between SSRIs/SNRIs and TCAs on pooled memory domains (SMD 0.33; 95% CI −0.11 to 0.78; p = 0.14), or between SSRIs and NDRIs on working memory (SMD −0.22; 95% CI −0.62 to 0.19). Sertraline outperformed fluoxetine on psychomotor speed (SMD 0.38; 95% CI 0.11–0.66; p = 0.006).
- A subgroup analysis found a greater positive effect in subjects younger than 65 (SMD 0.23; 95% CI 0.04–0.43; p = 0.02) than in those older than 65 (SMD 0.10; 95% CI 0.00–0.21; p = 0.06), but the difference between subgroups was not statistically significant (p = 0.24).
Methods
- Systematic review and meta-analysis of randomized clinical trials published before April 15, 2015, identified through Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Inclusion required adults over 18 with MDD, antidepressant monotherapy with monoamine modulation, and cognition assessed by standardized validated measures.
- Data were pooled using standard mean differences (SMD) with a random-effects model in Review Manager 5.3. Placebo-controlled trials compared final cognitive scores of antidepressant versus placebo; head-to-head trials compared one antidepressant with another. Risk of bias was assessed across five domains, and a funnel plot was created for psychomotor speed.
- Searches yielded 1,084 articles plus 23 from reference lists; 45 full texts were reviewed, 25 studies were included qualitatively, and 17 were included quantitatively. Nine placebo-controlled trials and eight head-to-head trials contributed to the meta-analysis.
Limitations
- The paper states that high heterogeneity of cognitive testing limited comparison and pooling, that moderate heterogeneity was present in pooled SMDs, that the number of studies and sample sizes were small, and that vortioxetine and duloxetine were heavily weighted; removing vortioxetine eliminated statistical significance for psychomotor speed.
- The paper also states that many included studies had potential for-profit bias due to pharmaceutical company funding, and that the functional meaning of the small cognitive test improvements remains largely unknown.
- Evident from the text: an Egger test could not be performed because fewer than ten studies were available, funnel plot interpretation was limited, most studies evaluated cognition as a secondary outcome, and responder/non-responder subgroup analyses were not possible due to insufficient reporting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









![Figure 10. Pooled effect on psychomotor speed (Digit Symbol Sign Test [DSST]) for sertraline versus fluoxetine. CI, confidence interval; SD, standard definition.](https://figures.cochat.ai/paper-figures/30fee3d872fd45778bc9237ce37a68a7/the-cognitive-effects-of-antidepressants-in-major-depressive-disorder-a-figure-10.jpg)
Verification
Claims the paper makes
5 Valid · 2 Not valid · 3 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several cognitive domains, including executive function, attention, memory, processing speed, and psychomotor skills, are affected during both symptomatic as well as “remitted” phases in MDD (Marazziti et al., 2010; Lee et al., 2012; Bora et al., 2013; Bortolato et al., 2014).”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Introduction
What the sources say
- Not checked — no full text of the sourcecites Marazziti et al., 2010 source
- Not checked — no full text of the sourcecites Lee et al., 2012 source
- Partly supportedcites Bora et al., 2013 sourceExperimental — accuracy not yet measured
The Cognitive domains results (page not provided) report poorer performance in euthymic MDD patients across the domains studied, including executive function, attention, memory, and processing speed. The Introduction says cognitive functions are often impaired in MDD, but this meta-analysis does not establish that every listed domain is affected during symptomatic phases; the Discussion addresses psychomotor inhibitory control specifically, not psychomotor skills broadly. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, since the publication of their review, several new clinical trials have been published that have primarily sought to determine the effects of antidepressants on cognitive function (Katona et al., 2012; McIntyre et al., 2014; Robinson et al., 2014; Soczynska et al., 2014; Gorlyn et al., 2015; Mahableshwarkar et al., 2015).”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Introduction
What the sources say
- Not checked — no full text of the sourcecites Katona et al., 2012 source
- Supportedcites McIntyre et al., 2014 source
The Discussion identifies this as a large randomized study in adults with major depressive disorder whose pre-defined primary clinical outcome was cognitive performance. It therefore supports citing McIntyre et al. (2014) as one of the trials primarily designed to test an antidepressant’s effects on cognition. (LLM, conf=0.94)
- Not matchedcites Robinson et al., 2014
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pooled effect size of both antidepressants (n = 989) versus placebo (n = 616) was 0.24 (95% CI 0.15 to 0.34; p < 0.00001), indicative of a small, yet statistically significant, positive effect”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Pooled Effect Sizes for Placebo-Controlled Trials
hedgedstates a causen = 989 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The SMD of all antidepressants (n = 984) versus placebo (n = 494) was 0.12 (95% CI -0.03 to 0.28; p = 0.12) is shown in Figure 6, indicative of a non–statistically significant effect.”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Pooled Effect Sizes for Placebo-Controlled Trials
hedgedn = 984- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified.”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Abstract > Results:
plainn = 2,550- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 46 claims and every source verdict.
- It may state two separate claims as one. 9
- Probably not a substantial claim. 5
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, a significant proportion of MDD patients continue to experience significant cognitive impairment.”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“A recent meta-analysis further indicates that standard antidepressant drugs may ameliorate certain cognitive domains in patients with MDD, namely psychomotor speed and delayed recall [20].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [20]
In the citing paper
“Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has been demonstrated to have procognitive effects compared to placebo.65”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [65]
In the citing paper
“However, the evidence base remains limited, and the effect sizes derived from this meta-analysis were small in magnitude (standard mean difference was 0.16 for psychomotor speed and 0.24 for delayed recall, respectively).”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Search Results and Study Characteristics
“Of the articles included in the quantitative review, nine were placebo-controlled randomized trials, with four trials evaluating two antidepressants compared to the same placebo group and the remaining evaluating a single antidepressant compared to placebo.”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Pooled Effect Sizes for Placebo-Controlled Trials
“In total, nine placebo-controlled studies evaluated psychomotor speed using DSST or a combined speed measure (Georgotas et al., 1989; Ferguson et al., 2003; Raskin et al., 2007; Hoffman et al., 2008; Culang et al., 2009; Katona et al., 2012; McIntyre et al., 2014; Robinson et al., 2014; Mahableshwarkar et al., 2015). Of these studies, three studies evaluated two agents in parallel compared to placebo”
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
A compendium of neuropsychological tests: administration, norms, and commentary
(1991) · Choice Reviews Online · doi:10.5860/choice.29-2400 · Cited by 6,120
Strauss, E., & Spreen, O. (2009) · Cited by 1,444
Kessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.9.1561 · Cited by 868 · cited 1×
“2 | International Journal of Neuropsychopharmacology, 2016 Introduction Major depressive disorder (MDD) is a highly prevalent and disabling illness affecting greater than 350 million people worldwide (Kessler et al., 2006).”
BackgroundKessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1561 · Cited by 868
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationA meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737
Cognitive impairment in euthymic major depressive disorder: a meta-analysis
Bora, E., Harrison, B. J., Yücel, M., & Pantelis, C. (2013) · Psychological Medicine · doi:10.1017/s0033291712002085 · Cited by 551 · cited 18×
“Due to the known persistence of cognitive dysfunction during remission (Bora et al., 2013) and demonstrated small positive effect of antidepressants on delayed recall and psychomotor speed, the investigation of other cognitively enhancing agents to be used adjunctively to current antidepressants…”
BackgroundInfluentialCognitive impairment in major depression
Marazziti, D., Consoli, G., Picchetti, M., Carlini, M., & Faravelli, L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.046 · Cited by 448
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · cited 4×
“Of these studies, one study (Katona et al., 2012) evaluated two agents in parallel compared to placebo, providing a total of five Ta b le 1 .”
BackgroundMethodInfluential
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
“In a metaanalysis (17 studies, N 1⁄4 3653) reviewing the cognitive effects of antidepressants based on neuropsychological tests, vortioxetine had the largest effects on processing speed, executive control, and cognitive control, while duloxetine had the largest effects on delayed recall.(17) The quality of these data…”
BackgroundSelf-citationMcIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationCarvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Cognitive function following a major depressive episode: a systematic review and meta-analysis
Semkovska, M., Quinlivan, L., O'Grady, T., Johnson, R., Collins, A., O'Connor, J., Knittle, H., Ahern, E., & Gload, T. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30291-3 · Cited by 631
Maj, M., Stein, D. J., Parker, G., Zimmerman, M., Fava, G. A., De Hert, M., Demyttenaere, K., McIntyre, R. S., Widiger, T., & Wittchen, H. (2020) · World Psychiatry · doi:10.1002/wps.20771 · Cited by 435
Self-citationCognitive impairment in depression: recent advances and novel treatments
Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199746 · Cited by 384
“Furthermore, it is the only antidepressant agent, among those to date evaluated, showing relatively strong evidence of a positive effect on multiple cognitive domains; for others (SSRIs, SNRIs and bupropione), on the other hand, the available evidence is still relatively weak.(67) Dovepress Perini et al”
BackgroundCognitive Impairment in Major Depressive Disorder
Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852918001207 · Cited by 320
“Hitherto, only 2 antidepressants (ie, duloxetine and vortioxetine) have demonstrated direct, independent, and clinically relevant effects on cognitive dysfunction in MDD.(8) The persistence of cognitive deficits after remission of depressive symptoms has been shown to contribute to the failure in achieving full functi…”
BackgroundSelf-citationCognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies
Solé, B., Jiménez, E., Torrent, C., Reinares, M., Bonnin, C. D. M., Torres, I., Varo, C., Grande, I., Valls, E., Salagre, E., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx032 · Cited by 299
Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder
Zuckerman, H., Pan, Z., Park, C., Brietzke, E., Musial, N., Shariq, A. S., Iacobucci, M., Yim, S. J., Lui, L. M. W., Rong, C., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00655 · Cited by 252
Self-citationCognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252
“A recent meta-analysis further indicates that standard antidepressant drugs may ameliorate certain cognitive domains in patients with MDD, namely psychomotor speed and delayed recall [20].”
Dementia Prevention and Treatment: A Narrative Review
Reuben, D. B., Kremen, S., & Maust, D. T. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8522 · Cited by 202
Prado, C. E., Watt, S., & Crowe, S. F. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9369-5 · Cited by 188
HIV, Depression, and Cognitive Impairment in the Era of Effective Antiretroviral Therapy
Rubin, L. H., & Maki, P. M. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00421-0 · Cited by 178
McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw055 · Cited by 185
“Evidence, although limited, suggests that mechanistically dissimilar antidepressants exert significantly positive effects on delayed recall and the cognitive substrates of psychomotor speed (Rosenblat et al., 2015).”
BackgroundSelf-citationMansur, R. B., Ahmed, J., Cha, D. S., Woldeyohannes, H. O., Subramaniapillai, M., Lovshin, J., Lee, J. G., Lee, J.-H., Brietzke, E., Reininghaus, E. Z., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.056 · Cited by 164
Self-citationKandola, A., Hendrikse, J., Lucassen, P. J., & Yücel, M. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00373 · Cited by 155
Gallagher, D., Fischer, C. E., & Iaboni, A. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716648296 · Cited by 155
“associated with depression or other neuropsychiatric disorders, and this is an area for further investigation.(81) Multicomponent interventions that address vascular risks and physical and cognitive inactivity in older adults at risk of further cognitive decline have demonstrated promise and may be particularly applic…”
BackgroundWang, B., Huang, X., Pan, X., Zhang, T., Hou, C., Su, W.-J., Liu, L.-L., Li, J.-M., & Wang, Y.-X. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.06.019 · Cited by 129
Baune, B. T., Brignone, M., & Larsen, K. G. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx070 · Cited by 140
“At least 3 recent reviews were conducted to investigate the effects of antidepressants on cognitive dysfunction (Baune and Renger, 2014; Keefe et al., 2014; Rosenblat et al., 2016).”
BackgroundResultMolecular aspects of depression: A review from neurobiology to treatment
Villas Boas, G. R., Boerngen de Lacerda, R., Paes, M. M., Gubert, P., Almeida, W. L. D. C., Rescia, V. C., de Carvalho, P. M. G., de Carvalho, A. A. V., & Oesterreich, S. A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.024 · Cited by 128
The neurocognitive profile of mood disorders – a review of the evidence and methodological issues
Porter, R. J., Robinson, L. J., Malhi, G. S., & Gallagher, P. (2015) · Bipolar Disorders · doi:10.1111/bdi.12342 · Cited by 124
Late-life depression and increased risk of dementia: a longitudinal cohort study
Ly, M. J., Karim, H. T., Becker, J. T., López, O. L., Anderson, S., Aizenstein, H. J., Reynolds, C. F., Zmuda, M. D., & Butters, M. A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01269-y · Cited by 142
Effects of chronic stress on cognitive function – From neurobiology to intervention
Girotti, M., Bulin, S. E., & Carreno, F. R. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100670 · Cited by 209
“…antidepressants have shown varying degrees of clinical efficacy regarding mood improvement, their impact on cognitive symptoms remains negligible (Rosenblat et al., 2015; Shilyansky et al., 2016), except for vortioxetine (Bennabi et al., 2019), a multi-modal drug that is the only FDA-approved…”
Lee, Y. L., Rosenblat, J. D., Lee, J., Carmona, N. E., Subramaniapillai, M., Shekotikhina, M., Mansur, R. B., Brietzke, E. M., Lee, J.-H., Ho, R., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.003 · Cited by 112
Self-citationThe use of antidepressants in oncology: a review and practical tips for oncologists
Grassi, L., Nanni, M., Rodin, G., Li, M., & Caruso, R. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx526 · Cited by 85
“Vortioxetine has a novel multimodal mechanism of action which is thought to help restore cognitive deficits associated with depression [22].”
BackgroundA Social Media Study on the Effects of Psychiatric Medication Use
Saha, K., Sugar, B., Torous, J., Abrahao, B., Kıcıman, E., & De Choudhury, M. (2019) · Proceedings of the International AAAI Conference on Web and Social Media · doi:10.1609/icwsm.v13i01.3242 · Cited by 96
“Given the pervasiveness of their use, psychiatric medications can either alleviate or exacerbate mental illness burden on both personal and societal levels (Rosenblat et al. 2016).”
BackgroundMethodResultInfluentialMisiak, B., Beszłej, J. A., Kotowicz, K., Szewczuk-Bogusławska, M., Samochowiec, J., Kucharska–Mazur, J., & Frydecka, D. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.021 · Cited by 93
“A recent meta-analysis of placebo-controlled randomized trials revealed that antidepressants improve psychomotor speed and delayed recall (Rosenblat et al., 2015).”
InfluentialGill, H., Gill, B., Rodrigues, N. B., Lipsitz, O., Rosenblat, J. D., El-Halabi, S., Nasri, F., Mansur, R. B., Lee, Y., & McIntyre, R. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.020 · Cited by 93
Self-citationThe link between long noncoding RNAs and depression
Huang, X., Luo, Y., Mao, Y.-S., & Jian-lin, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.06.004 · Cited by 98
“In major depression, cognitive impairment is common (Otte et al., 2015; Rosenblat et al., 2015; Galecki et al., 2015).”
BackgroundVortioxetine: A Review in Cognitive Dysfunction in Depression
Frampton, J. E. (2016) · Drugs · doi:10.1007/s40265-016-0655-3 · Cited by 90
“Some conventional antidepressants, including SSRIs and SNRIs, may to a degree improve cognitive deficits associated with MDD, although the majority of supporting studies have been limited by small sample sizes, absence of placebo controls, a lack of pre-specification of cognition as a primary outcome, and an inability…”
BackgroundCognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management
Chakrabarty, T., Hadjipavlou, G., & Lam, R. W. (2016) · Focus · doi:10.1176/appi.focus.20150043 · Cited by 84
Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant
Sowa-Kućma, M., Pańczyszyn-Trzewik, P., Misztak, P., Jaeschke, R. R., Sendek, K., Styczeń, K., Datka, W., & Koperny, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.01.030 · Cited by 86
Treating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 84
Self-citationRhee, T. G., Shim, S. R., Manning, K. J., Tennen, H. A., Kaster, T. S., d’Andrea, G., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., & Steffens, D. C. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000535665 · Cited by 101
“To date, relatively few interventions have been shown to improve cognitive functioning in MDD [66, 67].”
BackgroundSelf-citationLongitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis
Lam, M., Lee, J., Rapisarda, A., See, Y. M., Yang, Z., Lee, S.-A., Rashid, N. A. A., Kraus, M., Subramaniam, M., Chong, S., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.1668 · Cited by 78
The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis
McIntyre, R. S., Lee, Y., Zhou, A. J., Rosenblat, J. D., Peters, E. M., Lam, R. W., Kennedy, S. H., Rong, C., & Jerrell, J. M. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000723 · Cited by 75
Self-citationVortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75
Depression and episodic memory across the adult lifespan: A meta-analytic review.
James, T., Weiss-Cowie, S., Hopton, Z. W., Verhaeghen, P., Dotson, V. M., & Duarte, A. (2021) · Psychological Bulletin · doi:10.1037/bul0000344 · Cited by 107
“…certain antidepressants on hippocampal neurogenesis (Boldrini et al., 2009;Micheli et al., 2018) and certain memory functions (Prado et al., 2018; Rosenblat et al., 2015), others have not (Deuschle et al., 2004; Nagane et al., 2014; T hi s do cu m en t is co py ri gh te d by th e A m er ic an P…”
BackgroundThe glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders
Peyrovian, B., Rosenblat, J. D., Pan, Z., Iacobucci, M., Brietzke, E. M., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.001 · Cited by 82
Self-citationCognitive dysfunction in major depression: From assessment to novel therapies
Atique-Ur-Rehman, H., & Neill, J. C. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.013 · Cited by 72
Miskowiak, K. W., Ott, C. V., Petersen, J. Z., & Kessing, L. V. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.09.641 · Cited by 77
“A recent meta-analysis assessing the effect of monoaminergic antidepressants versus placebo in nine studies demonstrated small beneficial effects on psychomotor speed and delayed recall, with no significant differences between drug classes (Rosenblat et al., 2016).”
BackgroundA meta-analysis of cognitive performance in melancholic versus non-melancholic unipolar depression
Zaninotto, L., Solmi, M., Veronese, N., Guglielmo, R., Ioime, L., Camardese, G., & Serretti, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.039 · Cited by 74
Kuwano, N., Kato, T. A., Setoyama, D., Sato-Kasai, M., Shimokawa, N., Hayakawa, K., Ohgidani, M., Sagata, N., Kubo, H., Kishimoto, J., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.01.014 · Cited by 69
“Patients with MDD show high suicidal risk, severe impairment of social functioning, and cognitive dysfunction (Dong et al., 2017; Kupferberg et al., 2016; Mann et al., 2005; Rosenblat et al., 2015).”
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
“A meta-analysis [50] showed that antidepressants overall had a positive effect on psychomotor speed domain[[and”
MethodCognitive dysfunctions in depression – significance, description and treatment prospects
Czerwińska, A., & Pawłowski, T. (2019) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/105415 · Cited by 85
“Research shows that classic anti-depressants (tricyclic antidepressants – TCA) are not very effective in treating cognitive dysfunction in patients with MDD, probably due to their anticholinergic effect [41].”
Cognitive Problems in Perimenopause: A Review of Recent Evidence
Metcalf, C. A., Duffy, K. A., Page, C. E., & Novick, A. M. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01447-3 · Cited by 92
“In individuals with major depressive disorder, antidepressants can improve aspects of cognition, particularly delayed recall [65].”
BackgroundColwell, M., Tagomori, H., Chapman, S., Gillespie, A. L., Cowen, P. J., Harmer, C. J., & Murphy, S. E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02249-6 · Cited by 74
“Indeed, in one meta-analysis, the effect of antidepressant treatment on cognition became non-significant when vortioxetine studies were excluded [26].”
BackgroundGalimberti, C., Bosi, M. F., Volontè, M., Giordano, F., Dell’Osso, B. M., & Viganò, C. A. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1757116 · Cited by 69
Can psychomotor disturbance predict ect outcome in depression?
van Diermen, L., Vanmarcke, S., Walther, S., Moens, H., Veltman, E. M., Fransén, E., Sabbe, B., van der Mast, R. C., Birkenhäger, T. K., & Schrijvers, D. L. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.07.009 · Cited by 66
Depression, obstructive sleep apnea and psychosocial health
McFarlane, S. I. (2017) · Sleep Medicine and Disorders International Journal · doi:10.15406/smdij.2017.01.00012 · Cited by 72
Physical exercise for late life depression: effects on cognition and disability
Neviani, F., Murri, M. B., Mussi, C., Triolo, F., Toni, G., Simoncini, E., Tripi, F., Menchetti, M., Ferrari, S., Ceresini, G., et al. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217000576 · Cited by 65
The effects of processing speed on memory impairment in patients with major depressive disorder
Zaremba, D., Kalthoff, I. S., Förster, K., Redlich, R., Grotegerd, D., Leehr, E. J., Meinert, S., Dohm, K., Bürger, C., Enneking, V., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.015 · Cited by 66
“Although our explorative analyses suggest that neither psychiatric medication not comorbidity had a significant effect on learning and memory performance, there is evidence that at least antidepressant treatment improves cognitive functioning (Rosenblat et al., 2016).”
Liang, S., Yu, W., Ma, X., Luo, S., Zhang, J., Sun, X., Luo, X., & Zhang, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.052 · Cited by 55
Ren, F.-F., Hillman, C. H., Wang, W., Li, R., Zhou, W.-S., Liang, W.-M., Yang, Y., Chen, F., & Chang, Y. (2024) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2024.100447 · Cited by 64
Voinescu, A., Petrini, K., Fraser, D. S., Lazarovicz, R.-A., Papavă, I., Fodor, L. A., & David, D. (2021) · Virtual Reality · doi:10.1007/s10055-021-00520-7 · Cited by 54
Tian, J., Liu, S., He, X., Xiang, H., Chen, J., Gao, Y., Zhou, Y., & Qin, X. (2018) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2018.07.002 · Cited by 50
Wang, G., Si, T., Li, L., Fang, Y., Wang, C., Wang, L., Tan, K. H. X., Ettrup, A., Eriksen, H. F., Luo, S., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s195505 · Cited by 55
Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.048 · Cited by 47
Self-citationChokka, P., Bougie, J., Rampakakis, E., & Proulx, J. (2019) · CNS Spectrums · doi:10.1017/s1092852918000913 · Cited by 48
“Major depressive disorder (MDD) is a highly prevalent, burdensome condition that affects more than 350 million people worldwide.(1,2) In Canada, the prevalence of MDD was found to be 3.”
BackgroundWang, L., Xue, Y., Cao, S., Xie, Y., Wu, C., Ruffaner‐Hanson, C. D., Tang, H., Teng, Z., Chen, J., & Tang, M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.114 · Cited by 49
Unpacking Major Depressive Disorder: From Classification to Treatment Selection
Kennedy, S. H., & Ceniti, A. K. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717748883 · Cited by 52
“To this end, treatment with vortioxetine, bupropion, or duloxetine in MDD patients with marked cognitive dysfunction may be among the most suitable choices, according to evidencebased guidelines,(33) and delayed recall and psychomotor speed may be facets of cognition that are improved most significantly with antidepre…”
MethodMillan, M. J., Rivet, J.-M., & Gobert, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116672342 · Cited by 45
Cullen, A. E., Tappin, B. M., Zunszain, P. A., Dickson, H., Roberts, R. E., Nikkheslat, N., Khondoker, M. R., Pariante, C. M., Fisher, H. L., & Laurens, K. R. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.07.002 · Cited by 50
Mitochondria: A Connecting Link in the Major Depressive Disorder Jigsaw
Sharma, S., & Akundi, R. S. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180302120322 · Cited by 46
Pagonabarraga, J., Álamo, C., Castellanos, M., Díaz, S., & Manzano, S. (2023) · Brain Sciences · doi:10.3390/brainsci13020318 · Cited by 51
Huang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac054 · Cited by 41
“McIntyre et al. concluded that vortioxetine had a significant positive effect on psychomotor speed and delayed recall (Rosenblat et al., 2016).”
BackgroundExploration of Major Cognitive Deficits in Medication-Free Patients With Major Depressive Disorder
Jin, L., Dong, Q., Lu, X., Sun, J., Zhang, L., Wang, M., Wan, P., Guo, H., Zhao, F., Ju, Y., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00836 · Cited by 43
Neurocognitive deficits in obsessive–compulsive disorder: A selective review
Rao, N., & Suhas, S. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_517_18 · Cited by 39
“[104] On the contrary, few studies have suggested improvement in neuropsychological test performance after treatment with SSRIs.[70,71,105] Overall,”
ResultNeuroplasticity, the Prefrontal Cortex, and Psychopathology-Related Deviations in Cognitive Control
Luciana, M. M., & Collins, P. F. (2022) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-081219-111203 · Cited by 53
Ahern, E., White, J., & Slattery, E. J. (2024) · Neuropsychology Review · doi:10.1007/s11065-023-09629-9 · Cited by 50
“Current pharmacological (Atique-Ur-Rehman & Neill, 2019; Rosenblat et al., 2015; Shilyansky et al., 2016) and non-pharmacological (Bernhardt et al., 2019; Brondino et al., 2017; Groves et al., 2021; Listunova et al., 2018) treatments show preliminary evidence for select cognitive improvements.”
InfluentialLiu, L., Lv, X., Zhou, S., Liu, Q., Wang, J., Tian, H., Zhang, K., Wei, J., Wang, C., Chen, Q., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.06.020 · Cited by 32
Cognitive Impairment Along the Course of Depression: Non-Pharmacological Treatment Options
Listunova, L., Roth, C., Bartolovic, M., Kienzle, J., Bach, C., Weisbrod, M., & Roesch-Ely, D. (2018) · Psychopathology · doi:10.1159/000492620 · Cited by 44
Meng, C., Feng, S., Hao, Z., Dong, C., & Liu, H. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105620 · Cited by 39
Luo, Y., Kuang, S., Xue, L., & Yang, J. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.09.010 · Cited by 37
Assessing and measuring cognitive function in major depressive disorder
Ragguett, R., Cha, D. S., Kakar, R., Rosenblat, J. D., Lee, Y. L., & McIntyre, R. S. (2016) · Evidence-Based Mental Health · doi:10.1136/eb-2016-102456 · Cited by 42
Self-citationChen, C., Jiang, W., Wang, W., Ma, X., Li, Y., Wu, J., Hashimoto, K., & Gao, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196023 · Cited by 37
Ren, F.-F., Alderman, B. L., Wang, W., Chen, F., Zhou, W.-S., Zong, W.-J., Liang, W.-M., & Chang, Y. (2023) · Sports Medicine · doi:10.1007/s40279-023-01869-2 · Cited by 41
“For instance, a meta-analysis including 2550 patients with depression indicated that commonly prescribed antidepressants including vortioxetine, duloxetine, paroxetine, citalopram, phenelzine, nortryptiline, and sertraline were not effective in improving EF [31].”
BackgroundHagen, B. I., Lau, B., Joormann, J., Småstuen, M. C., Landrø, N. I., & Stubberud, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.015 · Cited by 37
Depressive disorders in the elderly and dementia: An update
Dias, N. S., Barbosa, I. G., Kuang, W., & Teixeira, A. L. (2020) · Dementia & Neuropsychologia · doi:10.1590/1980-57642020dn14-010001 · Cited by 41
Nykamp, M. J., Zorumski, C. F., Reiersen, A. M., Nicol, G. E., Cirrito, J. R., & Lenze, E. J. (2021) · Pharmacopsychiatry · doi:10.1055/a-1686-9620 · Cited by 35
Moreno, M., Goerigk, S. A., Bertola, L., Suemoto, C. K., Razza, L. B., Moffa, A. H., Veronezi, B. P., Tort, L. C., Nogueira, B. S., Gattaz, W. F., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.009 · Cited by 36
Is major depression a cognitive disorder?
Fossati, P. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2018.01.365 · Cited by 43
Jiao, K., Xu, H., Teng, C., Song, X., Xiao, C., Fox, P. T., Zhang, N., Wang, C., & Zhong, Y. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112381 · Cited by 29
Depression and Cognitive Function in Mild Cognitive Impairment: A 1-Year Follow-Up Study
Yoon, S., Shin, C., & Han, C. (2017) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988717723741 · Cited by 38
Santos‐García, D., Losada, M. G. A., Hernando, I. C., Cabo, I., Baña, R. M. Y., Redondo, R. A., González, J. M. P., Bartolomé, C. C., Painceiras, M. J. F., Alvarado, M. C. Í., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12111466 · Cited by 32
Mental Health Coping Stories on Social Media: A Causal-Inference Study of Papageno Effect
Yuan, Y., Saha, K., Keller, B., Isometsä, E. T., & Aledavood, T. (2023) · International World Wide Web Conference (WWW) · doi:10.1145/3543507.3583350 · Cited by 57
“Prior research notes the comorbidity of multiple mental health conditions [41], and we operationalize the language indicative of different mental health symptomatic expressions of depression, anxiety, stress, and suicidal ideation [45].”
BackgroundMcIntyre, R. S., Rosenblat, J. D., Rodrigues, N. B., Lipsitz, O., Chen-Li, D. C. J., Lee, J. G., Nasri, F., Subramaniapillai, M., Kratiuk, K., Wang, A., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113993 · Cited by 38
Self-citationCognitive functioning and lifetime major depressive disorder in UK Biobank
de Nooij, L., Harris, M. A., Adams, M. J., Clarke, T., Shen, X., Cox, S. R., McIntosh, A. M., & Whalley, H. C. (2020) · European Psychiatry · doi:10.1192/j.eurpsy.2020.24 · Cited by 35
“Meta-analyses suggest that some antidepressants may improve cognition [28,29], but these results appear to be specific to particular treatments [30–32], while for other treatments, medication side-effects may potentially affect cognitive performance negatively [6,14,33].”
BackgroundPredictors of cognitive impairment in treatment-resistant depression
Gregory, E., Torres, I. J., Ge, R., Blumberger, D. M., Downar, J. H., Daskalakis, Z. J., Lam, R. W. M., & Vila‐Rodriguez, F. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.101 · Cited by 31
Nikolin, S., Tan, Y. Y., Martin, D. M., Moffa, A. H., Loo, C. K. A., & Boonstra, T. W. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.083 · Cited by 35
Bergfeld, I. O., Mantione, M. H. M., Hoogendoorn, M. L. C., Ruhé, H. G., Horst, F., Notten, P., van Laarhoven, J., van den Munckhof, P., Beute, G. N., Schuurman, P. R., et al. (2017) · Psychological Medicine · doi:10.1017/s0033291717000113 · Cited by 33
“However, antidepressants most probably do not impact or only have a small positive effect on cognitive functioning (Baune & Renger, 2014; Rosenblat et al. 2015).”
BackgroundVortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update
Adamo, D., Calabria, E., Coppola, N., Pecoraro, G., & Mignogna, M. D. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211034320 · Cited by 38
Zhou, M., Liu, Z., Yu, J. H., Li, S., Tang, M., Zeng, L., Wang, H., Xie, H., Peng, L., Huang, H., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.010 · Cited by 31
Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults
Matt, S. M., & Gaskill, P. J. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146398 · Cited by 27
“However, treating depression in non-HIV individuals has generally been shown to improve cognition (Rosenblat et al., 2015), and further attempts to use antidepressants therapeutically should be evaluated for the aging HIV population in the future.”
BackgroundCabarcos-Fernández, P., Tabernero, M. J., Álvarez-Freire, I., & Bermejo, A. M. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab003 · Cited by 33
“It is estimated that more than 350 million people worldwide are currently diagnosed with such condition, being women more frequently affected than men (2).”
BackgroundRiga, M. S., Teruel‐Martí, V., Sánchez, C., Celada, P., & Artigas, F. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.024 · Cited by 32
Rao, D., Xu, G., Lu, Z., Liang, H., Lin, K., & Tang, M. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s226405 · Cited by 29
“A meta-analysis showed that antidepressants had a significant positive effect on psychomotor speed, but the effect on executive function did not reach statistical significance in head-tohead trials of tricyclic antidepressants, selective serotonin reuptake inhibitors, selective serotonin and norepinephrine reuptake in…”
BackgroundLam, R. W. M., Iverson, G. L., Evans, V. C., Yatham, L. N., Stewart, K., Tam, E. M., Axler, A., & Woo, C. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.074 · Cited by 28
Ketamine for bipolar depression: an updated systematic review
Fancy, F., Haikazian, S., Johnson, D. E., Chen-Li, D. C. J., Levinta, A., Husain, M. I., Mansur, R. B., & Rosenblat, J. D. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231202723 · Cited by 37
Self-citation
Metadata
- Authors
- Rosenblat, J. D., Kakar, R., & McIntyre, R. S.
- Affiliations
- Western University (CA)
- Corresponding author
- McIntyre, Roger S
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-25
- Volume
- 19
- Issue
- 2
- Pages
- pyv082
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4772818
- OpenAlex
- W2212064423
- Semantic Scholar
- af52beccf94ac5808c5f0857633e857371da9c0d
- Cited by
- 315
- References
- 32
- Citations by year
- 2026: 8 · 2025: 27 · 2024: 43 · 2023: 34 · 2022: 28 · 2021: 32 · 2020: 23 · 2019: 35 · 2018: 27 · 2017: 27 · 2016: 27 · 2015: 3
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- major depressive disorder, antidepressants, cognitive impairment, psychomotor speed, delayed recall, executive function, cognitive control, vortioxetine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants
- MeSH terms
- Antidepressive Agents, Cognition, Cognition Disorders, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.